摘要
目的:研究干细胞表面标志物CD133在肝癌组织中的表达及其与临床特征的关系,并探讨与预后的相关性.方法:用免疫组织化学Envision两步法检测52例肝细胞癌组织中CD133及Ki-67的表达,对照组6例为正常肝组织.对临床病理学指标和术后生存率进行比较分析.结果:52例肝癌组织中CD133表达的平均染色强度为1.07±0.32.按照Edmondson病理分级:Ⅰ～Ⅱ级肝癌组织的CD133平均染色强度为0.67±0.18,Ⅲ～Ⅳ级为1.17±0.24,2组间差异有统计学意义(F=62.96,P<0.05).TNM临床Ⅰ～Ⅱ期肝癌组织中CD133的平均染色强度为0.71±0.20,Ⅲ～Ⅳ期为1.19 ±0.29,2组间差异有统计学意义(F=57.13,P<0.05),但CD133的表达与患者年龄、性别、肿瘤的大小无关.Ki-67在肝癌组织阳性表达率为57.7%,Ki-67的表达与肝癌的分化和临床分期相关(F=8.56,7.45,P<0.05);CD133与Ki-67的表达呈正相关(F=18137,P<0.05);CD133阴性患者平均生存率较阳性患者显著延长(P<0.05).结论:CD133可能与肝癌的发生、发展相关,有望成为判断患者预后的指标之一.
Abstract
AIM: To assess the significance of CD133 expression in hepatocellular carcinoma ( HCC ) and its correlation with clinical features and prognosis of the tumor. MKTHODS: Fifty-two cases of HCC and 6 cases of normal liver specimens were evaluated by two-step methods of Envision immunohistochemical staining against CD133 and Ki-67. Correlation study was conducted between the expressions of CD133 and Ki-67 and clinicopatho-logical and survival rates after hepateetomy. RESULTS: The average intensity of CD133 expression on 52 HCCs was 1. 07 ± 0.32. The CD133 expressions were significantly associated with histological grades and clinical stages (F = 62.96 & 57. 13, P < 0. 05) , but not with age, gender and tumor size. The Ki-67 positive expression rate was 57. 7% in HCC. The Ki-67 expressions were also significantly associated with histological grades and clinical stages(F = 8.56 & 7.45, P<0.05). There was a positive correlation between the expressions of CD133 and Ki67 ( F — 18.37, P < 0.05). The survival time of CD133 negative patients was significantly longer than that of CD133 positive patients(P < 0.05). CONCLUSION: CD133 expression correlates positively with the progression of HCC and may potentially serve as a marker for HCC prognosis.
NETL
NSTL
维普
万方数据